{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:18:25Z","timestamp":1783048705949,"version":"3.54.6"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1160.18.210"],"award-info":[{"award-number":["NWA.1160.18.210"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The expanding geographical spread of Usutu virus (USUV) poses an increasing threat to bird populations and to human health. Here we assessed a chimeric USUV vaccine candidate that was constructed using the live attenuated yellow fever virus (YFV) YF-17D platform. In our chimeric virus, the pre-membrane (PrM) and envelope (E) proteins of YFV were replaced with those of USUV. Similar chimeras of YF-17D with otherflaviviruses have been reported to be attenuated in vivo, making them promising modified live virus vaccine candidates. We used either wild type USUV PrME or USUV PrME containing rationally designed mutations in the E protein that were expected to (further) attenuate the virus, based on their effect in the context of other orthoflaviviruses. In cell culture the YF-17D\/USUV chimeric viruses displayed reduced fitness compared to both YF-17D and USUV, with the chimera containing the mutated USUV E exhibiting the slowest growth kinetics. However, in our interferon \u03b1\/\u03b2 receptor deficient (Ifnar\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    ) mouse model the chimeric YF-17D\/USUV viruses caused rapid lethality in all animals, with survival times that were only marginally better compared to wild type USUV. It was surprising that introduction of the PrME region from the naturally low pathogenic USUV into the YF-17D platform yielded viruses that caused lethal infections in our model, while in contrast other neuroinvasive orthoflaviviruses are attenuated in this same chimeric platform. All control mice that were infected with a 1000-fold higher dose of YF-17D survived. We also discovered that the mutations in E that are attenuating in related viruses did not result in attenuation in the Ifnar\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mouse model, neither in the context of USUV itself or the YF-17D chimera. This may be due to the immunocompromised nature of the mice or because these mutations are not attenuating in the context of USUV. This work highlights some complications and unpredictability related to the use of the chimeric live attenuated YF-17D vaccine platform and introduction of rationally designed mutations with a predicted attenuating effect. Furthermore, our work illustrates that infection models that are able to better predict the phenotype and safety of (chimeric) USUV\/orthoflavivirus vaccine candidates are needed.\n                  <\/jats:p>","DOI":"10.1186\/s12985-026-03145-x","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:55:05Z","timestamp":1783047305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A yellow fever 17D and Usutu virus chimera with rationally designed mutations in the envelope protein is lethal in an Ifnar-\/- mouse model"],"prefix":"10.1186","volume":"23","author":[{"given":"Johanna M.","family":"Duyvestyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Bredenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Thaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Kikkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"van Hemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"3145_CR1","doi-asserted-by":"crossref","unstructured":"Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nature Microbiology 2020 5:6 5, 796\u2013812 (2020).","DOI":"10.1038\/s41564-020-0714-0"},{"key":"3145_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.715759","volume":"9","author":"B Chala","year":"2021","unstructured":"Chala B, Hamde F. Emerging and re-emerging vector-borne infectious diseases and the challenges for control: a review. Front Public Health. 2021;9:715759.","journal-title":"Front Public Health"},{"key":"3145_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/v15040860","author":"SK Dutta","year":"2023","unstructured":"Dutta SK, Langenburg T. A Perspective on Current Flavivirus Vaccine Development: A Brief Review. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15040860.","journal-title":"Viruses"},{"key":"3145_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.aivir.2024.09.002","volume":"120","author":"SC Kuchinsky","year":"2024","unstructured":"Kuchinsky SC, Duggal NK. Usutu virus, an emerging arbovirus with one health importance. Adv Virus Res. 2024;120:39\u201375.","journal-title":"Adv Virus Res"},{"key":"3145_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/v15010077","author":"D Cadar","year":"2022","unstructured":"Cadar D, Simonin Y. Human Usutu Virus Infections in Europe: A New Risk on Horizon? Viruses. 2022. https:\/\/doi.org\/10.3390\/v15010077.","journal-title":"Viruses"},{"key":"3145_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/v9010020","author":"J Yang","year":"2017","unstructured":"Yang J, et al. Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain. Viruses. 2017. https:\/\/doi.org\/10.3390\/v9010020.","journal-title":"Viruses"},{"key":"3145_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.14.7418-7426.2004","volume":"78","author":"N Charlier","year":"2004","unstructured":"Charlier N, et al. Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice. J Virol. 2004;78:7418.","journal-title":"J Virol"},{"key":"3145_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/v14102213","volume":"14","author":"B Khare","year":"2022","unstructured":"Khare B, Kuhn RJ. The Japanese encephalitis antigenic complex viruses: from structure to immunity. Viruses. 2022;14:2213.","journal-title":"Viruses"},{"key":"3145_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/v15040813","author":"B Wu","year":"2023","unstructured":"Wu B, Qi Z, Qian X. Recent Advancements in Mosquito-Borne Flavivirus Vaccine Development. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15040813.","journal-title":"Viruses"},{"issue":"9","key":"3145_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/v11090823","volume":"11","author":"JA Kaiser","year":"2019","unstructured":"Kaiser JA, Barrett ADT. Twenty years of progress toward West Nile virus vaccine development. Viruses. 2019;11(9):823.","journal-title":"Viruses"},{"key":"3145_CR11","doi-asserted-by":"crossref","unstructured":"van Bree JWM et al. Novel approaches for the rapid development of rationally designed arbovirus vaccines. One Health. 2023;16.","DOI":"10.1016\/j.onehlt.2023.100565"},{"key":"3145_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vaccine.2014.10.004","volume":"33","author":"TP Monath","year":"2015","unstructured":"Monath TP, et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk\/benefit assessment. Vaccine. 2015;33:62\u201372.","journal-title":"Vaccine"},{"key":"3145_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","volume":"28","author":"B Guy","year":"2010","unstructured":"Guy B, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28:632\u201349.","journal-title":"Vaccine"},{"key":"3145_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1128\/JVI.75.2.934-942.2001","volume":"75","author":"J Arroyo","year":"2001","unstructured":"Arroyo J, et al. Molecular basis for attenuation of neurovirulence of a yellow fever virus\/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol. 2001;75:934\u201342.","journal-title":"J Virol"},{"key":"3145_CR15","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","volume":"73","author":"TJ Chambers","year":"1999","unstructured":"Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever\/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol. 1999;73:3095\u2013101.","journal-title":"J Virol"},{"key":"3145_CR16","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1128\/JVI.75.9.4268-4275.2001","volume":"75","author":"SL Allison","year":"2001","unstructured":"Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol. 2001;75:4268\u201375.","journal-title":"J Virol"},{"key":"3145_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.virol.2009.10.027","volume":"396","author":"CYH Huang","year":"2010","unstructured":"Huang CYH, et al. The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion. Virology. 2010;396:305\u201315.","journal-title":"Virology"},{"key":"3145_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.virol.2006.10.033","volume":"360","author":"NB Trainor","year":"2007","unstructured":"Trainor NB, Crill WD, Roberson JA, Chang GJJ. Mutation analysis of the fusion domain region of St. Louis encephalitis virus envelope protein. Virology. 2007;360:398\u2013406.","journal-title":"Virology"},{"key":"3145_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.virol.2006.05.025","volume":"353","author":"S Zhang","year":"2006","unstructured":"Zhang S, et al. A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus. Virology. 2006;353:35\u201340.","journal-title":"Virology"},{"key":"3145_CR20","doi-asserted-by":"publisher","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","volume":"78","author":"J Arroyo","year":"2004","unstructured":"Arroyo J, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol. 2004;78:12497\u2013507.","journal-title":"J Virol"},{"key":"3145_CR21","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1471-4914(01)02048-2","volume":"7","author":"J Arroyo","year":"2001","unstructured":"Arroyo J, Miller CA, Catalan J, Monath TP. Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med. 2001;7:350.","journal-title":"Trends Mol Med"},{"key":"3145_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107408118","volume":"118","author":"B Khare","year":"2021","unstructured":"Khare B, Klose T, Fang Q, Rossmann MG, Kuhn RJ. Structure of Usutu virus SAAR-1776 displays fusion loop asymmetry. Proc Natl Acad Sci U S A. 2021;118:e2107408118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3145_CR23","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.45.30391","volume":"21","author":"JM Rijks","year":"2016","unstructured":"Rijks JM, et al. Widespread Usutu virus outbreak in birds in the Netherlands, 2016. Euro Surveill. 2016;21:30391.","journal-title":"Euro Surveill"},{"key":"3145_CR24","doi-asserted-by":"crossref","unstructured":"Duyvestyn JM et al. Dose and strain dependent lethality of Usutu virus in an Ifnar\u2013\/\u2013 mouse model. npj Viruses 2025 3:1 3, 1\u201313 (2025).","DOI":"10.1038\/s44298-025-00089-x"},{"key":"3145_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1099\/vir.0.18860-0","volume":"84","author":"PJ Bredenbeek","year":"2003","unstructured":"Bredenbeek PJ, et al. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol. 2003;84:1261\u20138.","journal-title":"J Gen Virol"},{"key":"3145_CR26","doi-asserted-by":"publisher","first-page":"9608","DOI":"10.1128\/jvi.71.12.9608-9617.1997","volume":"71","author":"BD Lindenbach","year":"1997","unstructured":"Lindenbach BD, Rice CM. Trans-complementation of yellow fever virus NS1 reveals a role in early RNA replication. J Virol. 1997;71:9608.","journal-title":"J Virol"},{"key":"3145_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-020-2294-9","volume":"582","author":"T Thi Nhu Thao","year":"2020","unstructured":"Thi Nhu Thao T, et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature. 2020;582:561.","journal-title":"Nature"},{"key":"3145_CR28","doi-asserted-by":"crossref","unstructured":"Oberacker P et al. Bio-On-Magnetic-Beads (BOMB): Open platform for high-throughput nucleic acid extraction and manipulation. PLoS Biol. 2019;17(1):e3000107.","DOI":"10.1371\/journal.pbio.3000107"},{"key":"3145_CR29","doi-asserted-by":"crossref","unstructured":"Chen Z et al. Crystal structure of Usutu virus envelope protein in the pre-fusion state. Virol J 2018;15(1):183.","DOI":"10.1186\/s12985-018-1092-6"},{"key":"3145_CR30","doi-asserted-by":"publisher","first-page":"5981","DOI":"10.1016\/j.vaccine.2008.08.064","volume":"26","author":"L Yu","year":"2008","unstructured":"Yu L, Robert Putnak J, Pletnev AG, Markoff L. Attenuated West Nile viruses bearing 3\u2019SL and envelope gene substitution mutations. Vaccine. 2008;26:5981\u20138.","journal-title":"Vaccine"},{"key":"3145_CR31","doi-asserted-by":"crossref","unstructured":"Wang X et al. Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability. Nat Commun. 2017;8(1):14.","DOI":"10.1038\/s41467-017-00024-6"},{"issue":"5","key":"3145_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13050495","volume":"13","author":"JM Duyvestyn","year":"2025","unstructured":"Duyvestyn JM, et al. Attenuating mutations in Usutu virus: towards understanding Orthoflavivirus virulence determinants and live attenuated vaccine design. Vaccines. 2025;13(5):495.","journal-title":"Vaccines"},{"key":"3145_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1080\/22221751.2020.1730709","volume":"9","author":"DB Kum","year":"2020","unstructured":"Kum DB, et al. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Emerg Microbes Infect. 2020;9:520.","journal-title":"Emerg Microbes Infect"},{"key":"3145_CR34","doi-asserted-by":"crossref","unstructured":"Salgado R et al. West Nile Virus Vaccination Protects against Usutu Virus Disease in Mice. Viruses 13, (2021).","DOI":"10.3390\/v13122352"},{"key":"3145_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.virol.2007.04.016","volume":"366","author":"TJ Chambers","year":"2007","unstructured":"Chambers TJ, Droll DA, Jiang X, Wold WSM, Nickells JA. JE nakayama\/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease. Virology. 2007;366:51\u201361.","journal-title":"Virology"},{"key":"3145_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0146-0","volume":"4","author":"JA Kaiser","year":"2019","unstructured":"Kaiser JA, et al. Japanese encephalitis vaccine-specific envelope protein E138K mutation does not attenuate virulence of West Nile virus. NPJ Vaccines. 2019;4:50.","journal-title":"NPJ Vaccines"},{"key":"3145_CR37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.virol.2015.10.015","volume":"487","author":"V Yamshchikov","year":"2016","unstructured":"Yamshchikov V, Manuvakhova M, Rodriguez E. Development of a human live attenuated West Nile infectious DNA vaccine: suitability of attenuating mutations found in SA14-14-2 for WN vaccine design. Virology. 2016;487:198\u2013206.","journal-title":"Virology"},{"key":"3145_CR38","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/43977","volume":"401","author":"S Lehrman","year":"1999","unstructured":"Lehrman S. Virus treatment questioned after gene therapy death. Nature. 1999;401:517\u20138.","journal-title":"Nature"},{"key":"3145_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1146\/annurev-virology-092818-015652","volume":"6","author":"E Genoyer","year":"2019","unstructured":"Genoyer E, L\u00f3pez CB. The impact of defective viruses on infection and immunity. Annu Rev Virol. 2019;6:547\u201366.","journal-title":"Annu Rev Virol"},{"key":"3145_CR40","doi-asserted-by":"crossref","unstructured":"Rezelj VV et al. Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts. Nature Communications 2021 12:1 12, 1\u201314 (2021).","DOI":"10.1038\/s41467-021-22341-7"},{"key":"3145_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00692-24","author":"JW Brennan","year":"2024","unstructured":"Brennan JW, Sun Y. Defective viral genomes: advances in understanding their generation, function, and impact on infection outcomes. mBio. 2024. https:\/\/doi.org\/10.1128\/mbio.00692-24.","journal-title":"mBio"},{"key":"3145_CR42","first-page":"1116","volume":"12","author":"E Benzarti","year":"2020","unstructured":"Benzarti E, Garigliany M. Vitro and In Vivo Models to Study the Zoonotic Mosquito-Borne Usutu Virus. Viruses 2020. 2020;12:1116.","journal-title":"Viruses 2020"},{"key":"3145_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.24272\/j.issn.2095-8137.2017.052","volume":"39","author":"G Wong","year":"2018","unstructured":"Wong G, Qiu XG. Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential. Zool Res. 2018;39:3\u201314.","journal-title":"Zool Res"},{"issue":"11","key":"3145_CR44","first-page":"35","volume":"11","author":"A Mar\u00edn-Lopez","year":"2019","unstructured":"Mar\u00edn-Lopez A, et al. Modeling Arboviral Infection in Mice Lacking the Interferon Alpha\/Beta Receptor. Viruses 2019. 2019;11(11):35.","journal-title":"Viruses 2019"},{"key":"3145_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101077","volume":"9","author":"S Tajima","year":"2021","unstructured":"Tajima S, et al. Immunogenicity and protective ability of genotype i-based recombinant japanese encephalitis virus (Jev) with attenuation mutations in e protein against genotype v jev. Vaccines. 2021;9:1077.","journal-title":"Vaccines"},{"key":"3145_CR46","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00705-012-1337-4","volume":"157","author":"DC Clark","year":"2012","unstructured":"Clark DC, Brault AC, Hunsperger E. The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system. Arch Virol. 2012;157:1423.","journal-title":"Arch Virol"},{"key":"3145_CR47","doi-asserted-by":"crossref","unstructured":"Mishra N et al. A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies. mBio 11, (2020).","DOI":"10.1128\/mBio.02494-19"},{"key":"3145_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0950268819001213","volume":"147","author":"M Cl\u00e9","year":"2019","unstructured":"Cl\u00e9 M, et al. Usutu virus: a new threat? Epidemiol Infect. 2019;147:1\u201311.","journal-title":"Epidemiol Infect"},{"key":"3145_CR49","doi-asserted-by":"crossref","unstructured":"Marshall EM, Koopmans M, Rockx B. Usutu virus and West Nile virus use a transcellular route of neuroinvasion across an in vitro model of the human blood\u2013brain barrier. npj Viruses 2024 2:1 2, 1\u20139 (2024).","DOI":"10.1038\/s44298-024-00034-4"},{"key":"3145_CR50","doi-asserted-by":"crossref","unstructured":"Zaccaria G et al. The envelope protein of Usutu virus attenuates West Nile virus virulence in immunocompetent mice. Vet Microbiol. 2021;263:109262.","DOI":"10.1016\/j.vetmic.2021.109262"},{"key":"3145_CR51","doi-asserted-by":"crossref","unstructured":"Harrison JJ et al. A chimeric vaccine derived from Australian genotype IV Japanese encephalitis virus protects mice from lethal challenge. npj Vaccines 2024 9:1 9, 1\u201314 (2024).","DOI":"10.1038\/s41541-024-00903-2"},{"key":"3145_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01724-24","author":"RF Rocha","year":"2025","unstructured":"Rocha RF, et al. Usutu virus-induced meningoencephalitis in immunocompetent mice is characterized by the recruitment of mononuclear cells and a proinflammatory T helper 1 response. J Virol. 2025. https:\/\/doi.org\/10.1128\/JVI.01724-24.","journal-title":"J Virol"},{"key":"3145_CR53","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.vaccine.2024.01.077","volume":"42","author":"ZJ Wang","year":"2024","unstructured":"Wang ZJ, et al. Development of a live-attenuated chimeric vaccine against the emerging Usutu virus. Vaccine. 2024;42:1363\u201371.","journal-title":"Vaccine"},{"key":"3145_CR54","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1016\/j.vaccine.2016.03.015","volume":"34","author":"MA Mart\u00edn-Acebes","year":"2016","unstructured":"Mart\u00edn-Acebes MA, et al. A recombinant DNA vaccine protects mice deficient in the alpha\/beta interferon receptor against lethal challenge with Usutu virus. Vaccine. 2016;34:2066\u201373.","journal-title":"Vaccine"},{"key":"3145_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00223","volume":"9","author":"M Chesnut","year":"2019","unstructured":"Chesnut M, et al. In vitro and in silico models to study mosquito-borne flavivirus neuropathogenesis, prevention, and treatment. Front Cell Infect Microbiol. 2019;9:223.","journal-title":"Front Cell Infect Microbiol"},{"key":"3145_CR56","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-56-2-363","author":"F Liprandi","year":"1981","unstructured":"Liprandi F. Isolation of plaque variants differing in virulence from the 17D strain of yellow fever virus. Journal of General Virology. 1981. https:\/\/doi.org\/10.1099\/0022-1317-56-2-363.","journal-title":"Journal of General Virology"},{"key":"3145_CR57","doi-asserted-by":"publisher","unstructured":"Khou C, Pardigon N. Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses. Intervirology vol. 60 8\u201318 Preprint at https:\/\/doi.org\/10.1159\/000479966 (2017).","DOI":"10.1159\/000479966"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03145-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03145-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:55:24Z","timestamp":1783047324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03145-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3145"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03145-x","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"16 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}